Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jul 9, 2012

Cobra Spinout Prokarium Acquires Emergent IP to Boost Oral Vaccine Initiative

  • The Cobra Biologics spinout Prokarium acquired Emergent BioSolutions’ live Salmonella-based typhoid vaccine Typhella™, and oral delivery platform spi-VEC™. Emergent has previously carried out Phase I and II clinical studies demonstrating that Typhella is safe and immunogenic as a typhoid vaccine.

    Prokarium has combined the Typhella and spi-VEC technologies with its own ORT-VAC™ (Operator-Repressor Titration for Vaccines) plasmid stabilization technology to generate a salmonella-based Vaxonella™ platform for the oral delivery of recombinant protein vaccines.

    The Vaxonella platform is being commercialized through licensing agreements, and Prokarium is focusing its own in-house research on the development of a dual oral vaccine candidate Typhetec™ against typhoid and ETEC (enterotoxigenic E.coli). Clinical trials with Typhetec are projected to start during 2013.

    Prokarium’s ORT-VAC™ technology (Operator-Repressor Titration for Vaccines) is the only selectable marker-free plasmid stabilization technology that can function with any type of plasmid, enabling recombinant antigens to be delivered orally.



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »